Concord Biotech Ltd NSE:CONCORDBIO:
CONCORD BIOTECH - COMPLETES ANVISA INSPECTION AT LIMBASI API MANUFACTURING FACILITY
Concord Biotech Completes Anvisa Inspection At Limbasi API Manufacturing Facility
On 6ix: 6ix.com/news/concord-biotech-completes-anvisa-inspection-at-limbasi-api-manufacturing-facility
Earlier from Concord Biotech
- Trade Spotlight: How should you trade Concord Biotech, Jindal Steel, Axis Bank, Aegis Logistics, Raymond, and others on June 11?
- Concord Biotech surges over 5% after USFDA approval for Tofacitinib tablets
- Concord Biotech shares jump 8% after US FDA clears firm's new drug
- Concord Biotech gets FDA nod for immunosuppressant mycophenolate mofetil
- CONCORDBIO: Revenue declined 12% in FY 2026, but strong growth and margin improvement are expected in FY 2027
Later from Concord Biotech
- Bertelsmann says US authorities have approved BMG/Concord merger
- Concord Biotech Completes PPB (Kenya) And NDA (Uganda) Inspection At Unit-Ii Formulation Facility
Follow Concord Biotech into a list and get an email when it puts out news.
Follow Concord Biotech